Rajesh Malik - 12 Feb 2024 Form 4 Insider Report for G1 Therapeutics, Inc. (GTHX)

Role
Chief Medical Officer
Signature
/s / Monica Roberts Thomas, attorney-in-fact
Issuer symbol
GTHX
Transactions as of
12 Feb 2024
Transactions value $
-$123,563
Form type
4
Filing time
13 Feb 2024, 18:14:36 UTC
Previous filing
08 Jan 2024
Next filing
15 May 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GTHX Common Stock Options Exercise $8,580 +28,600 +17% $0.3* 198,538 12 Feb 2024 Direct
transaction GTHX Common Stock Sale -$132,143 -28,600 -14% $4.62 169,938 12 Feb 2024 Direct F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GTHX Stock Option (Right to Buy) Options Exercise $0 -28,600 -100% $0* 0 12 Feb 2024 Common Stock 28,600 $0.3 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
F2 The price represents the weighted average price with a low of $4.45 and a high of $4.75. The Reporting Person undertakes to provide G1 Therapeutics, Inc., any security holder of G1 Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote 2 to this Form 4.
F3 Represents (i) 75,463 shares of common stock; (ii) 2,750 restricted stock units ("RSUs") from award granted on January 4, 2021; (iii) 6,000 RSUs from award granted on January 3, 2022; (iv) 13,425 RSUs from award granted on January 3, 2023; (v) 35,000 RSUs from award granted on May 10, 2023; and (vi) 37,300 RSUs from award granted on January 3, 2024.
F4 All shares underlying this option have vested.